A

Amgen

Makes biotech medicines for serious illnesses

Executive Director – U.S. Brand Lead - Neurology, Rare Disease

Full-TimeUpdated on 10/24/2026
$262.5k - $355.2k/yr+ Discretionary annual bonus + Stock-based long-term incentives
Expert
Bachelor's, Master's, MBA, PhD
Remote in USA
Remote
Growth & MarketingBrand & Creative Marketing

About the job

Requirements
  • A doctorate degree and 6 years of marketing and/or commercial experience; or a master's degree and 10 years of marketing and/or commercial experience; or a bachelor's degree and 12 years of marketing and/or commercial experience.
  • At least 6 years of managerial experience directly managing people and/or leadership experience leading teams, projects, programs, or directing resource allocation.
  • Progressive leadership experience in U.S. biopharmaceutical marketing, including accountability for an inline or recently launched brand in a competitive specialty market.
  • Experience in rare disease and/or neurology; experience in generalized myasthenia gravis, neuromyelitis optica spectrum disorder, neuroimmunology, infusion-based therapies, or high-value biologics.
  • Success accelerating post-launch growth and translating performance insights into business results.
  • Commercial experience across health care professional and patient marketing, omnichannel engagement, field execution, market access, patient services, forecasting, analytics, and financial management.
  • Experience owning brand budgets and forecasts, setting performance measures, prioritizing investments, and communicating business performance to senior leadership.
  • Understanding of the U.S. payer, reimbursement, specialty distribution, buy-and-bill, and site-of-care environment relevant to rare disease therapies.
  • A track record of building high-performing teams and creating strong team culture.
  • Biosimilar commercialization experience or the ability to lead across distinct business models and markets.
  • Experience influencing senior stakeholders in a matrixed organization.
  • Experience navigating medical, legal, regulatory, and compliance review processes.
  • Approximately 25% travel, including overnight and occasional weekend commitments; routine travel to Deerfield is not included in this estimate.
  • Candidates may live anywhere in the U.S. with access to a major airport.
  • Ability to ensure strategies, materials, and activities comply with applicable legal, regulatory, ethical, and company requirements.
Responsibilities
  • Own the U.S. commercial strategy and annual and long-range plans for UPLIZNA in generalized myasthenia gravis and neuromyelitis optica spectrum disorder, and for BKEMV, consistent with the cross-indication strategy and direction set by the General Manager.
  • Own the Neurology forecast and its commercial assumptions, with inputs and support from Forecasting, Data & Analytics, and Finance.
  • Own the Neurology and BKEMV budgets and allocate resources against approved priorities; recommend changes in investment to the General Manager as business needs evolve.
  • Deliver revenue and profitability objectives by identifying growth opportunities, addressing barriers, and making timely changes to strategy, execution, targeting, channel mix, and investment.
  • Lead development and execution of integrated brand plans across health care professional, patient and caregiver, digital and omnichannel, peer-to-peer, congress, field, access, and patient services channels.
  • Work with Portfolio Strategy, Omnichannel, and Thought Leader Liaison teams to drive integrated execution.
  • Establish priorities, governance, decision rights, milestones, and accountability across the cross-functional brand team.
  • Collaborate with Sales Leadership and Training on field strategy, training, tools, messaging, and customer engagement resources; maintain a regular feedback loop between field and brand teams.
  • Oversee agency and vendor partners, including strategic direction, quality, resource use, and delivery of priority work.
  • Set objectives and performance measures and lead regular reviews of patient, customer, market, access, competitive, channel, and execution trends.
  • Partner with Brand Analytics & Insights, Market Research, Sales, Thought Leader Liaisons, and Finance to translate data into business decisions and executive-level performance updates.
  • Lead scenario planning and mitigation across competitive, access, reimbursement, operational, supply, and policy considerations.
  • Partner with the General Manager, IgG4-RD brand team, and cross-indication Portfolio Strategy team on UPLIZNA positioning, core messaging, customer experience, shared capabilities, and portfolio investment choices.
  • Partner with Market Access, Value & Access, Patient Services, and field teams to address barriers across diagnosis, referral, access, treatment initiation, and continuity of therapy.
  • Collaborate with the Thought Leader Liaison team to ensure strategy is executed appropriately across this field-based team.
  • Provide commercial input into evidence-generation priorities based on customer, patient, access, and competitive needs, in partnership with Medical and Value & Access and in accordance with applicable governance requirements.
  • Represent the U.S. Neurology business in governance forums and appropriate external engagements, and provide input to global strategy, lifecycle planning, and future growth opportunities.
  • Own U.S. BKEMV strategy, budget, performance, and cross-functional alignment within the broader Amgen biosimilars strategy.
  • Lead the BKEMV marketing team in navigating customer and channel dynamics, access and contracting considerations, competitive response, and value communication.
  • Use shared capabilities where they add value while preserving the distinct strategies, customers, and operating requirements of UPLIZNA and BKEMV.
  • Serve as a member of the Neurology & IgG4-RD Leadership Team and contribute to business strategy, talent, culture, and organizational effectiveness.
  • Lead the cross-functional brand team across Marketing, Sales, Medical, Market Access, Patient Services, Value & Access, Digital, Data & Analytics, Finance, Corporate Affairs, Regulatory, Legal, Compliance, Operations, and Global Commercial; functional leaders retain accountability for decisions within their functions.
  • Build, develop, and retain an effective marketing team; set expectations, coach talent, and create development and succession opportunities.
  • Ensure strategies, materials, and activities comply with applicable legal, regulatory, ethical, and company requirements.
Desired Qualifications
  • Advanced degree, such as an MBA.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget
  • Conference Attendance Budget

Company News

PR Newswire
Oct 26th, 2026
Amgen appoints former Yum! Brands CEO David Gibbs to its board

Amgen has appointed David W. Gibbs to its board of directors, effective immediately. He will serve on the Audit Committee and the Compensation and Management Development Committee. Gibbs recently retired as president and chief executive officer of Yum! Brands, owner of Taco Bell and Kentucky Fried Chicken. As chief executive from 2020 to 2025, he led its digital transformation and expanded it to nearly 61,000 locations. He has sat on the board of Under Armour since 2021 and PepsiCo since 2026. "His experience creating direct relationships with customers will help inform how we prepare for future launches," said Robert A. Bradway, Amgen's chairman and chief executive officer. The board now has 13 directors, 12 of them independent.

Yahoo Finance
Oct 26th, 2026
ESMO 2026: Moderna vaccine debate, Roche's $3.6B KRAS bet and Amgen's lung cancer data

Three cancer drug trials drew attention at the European Society for Medical Oncology (ESMO) meeting, with investors and analysts weighing the results. Moderna and Merck's vaccine intismeran autogene cut the relative risk of melanoma recurrence or death by 42% in a Phase 3 trial. Moderna's shares have still fallen by double digits since the results leaked early, as investors question its valuation and the vaccine's manufacturing and commercial potential. Roche's divarasib reduced the risk of death or disease progression by 42% in KRAS G12C lung cancer, beating Krazati and Lumakras. Patients lived a median of about 18 months, versus a year. Roche raised its peak sales forecast from 3.6 billion Swiss francs to 3 billion. Amgen's Imdelltra, combined with Imfinzi, cut the risk of death by 58% in small cell lung cancer. Median survival was 21.1 months, against 12.7 months for Imfinzi alone.

Yahoo Finance
Oct 25th, 2026
Amgen vs Gilead: Which biotech dividend stock is the better buy, with yields of 2.2% and 2.1%?

Amgen and Gilead Sciences, two of the few big biotech companies that pay dividends, suit different kinds of income investors, according to a comparison by The Motley Fool's Keith Speights. Amgen offers a forward dividend yield above 2.2%, against slightly below 2.1% for Gilead. Gilead has the lower payout ratio, at 43.5% versus 60.9%, and the cheaper valuation: 15.6 times forward earnings against 16.7. Amgen's product sales grew 9% year over year in its latest quarter, against 8% for Gilead. It has 17 drugs on track to be blockbusters this year, versus eight for Gilead, and 29 late-stage programs. Speights favours Amgen for yield and growth, and Gilead for safety and value.

Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 22nd, 2026
Eli Lilly vs Amgen: $65.2B revenue and 45% growth against a cheaper stock for 2026

Eli Lilly is growing far faster than Amgen, but investors pay a steep premium for it. The article's author favours Lilly for long-term investors in 2026. Lilly's FY 2025 revenue rose 45% to about $65.2 billion, with net income of $20.6 billion and a 32% net margin. Amgen's revenue grew about 10% to $36.7 billion, with net income of $7.7 billion and a 21% margin. Lilly trades at a forward P/E of 38.3x against Amgen's 19.4x. Its debt-to-equity ratio is about 1.6x, compared with nearly 6.3x for Amgen. Lilly's growth rests on its GLP-1 drugs Zepbound and Mounjaro. The article projects 2026 revenue of $88.7 billion, against about $37.8 billion for Amgen.